A detailed history of Center Book Partners LP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Center Book Partners LP holds 11,908 shares of CPRX stock, worth $276,027. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,908
Previous 14,939 20.29%
Holding current value
$276,027
Previous $324,000 27.78%
% of portfolio
0.01%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025

SELL
$19.13 - $22.22 $57,983 - $67,348
-3,031 Reduced 20.29%
11,908 $234,000
Q2 2025

Aug 12, 2025

BUY
$21.4 - $26.31 $319,694 - $393,045
14,939 New
14,939 $324,000
Q3 2023

Nov 13, 2023

BUY
$11.69 - $15.02 $26,407 - $33,930
2,259 Added 19.96%
13,577 $158,000
Q2 2023

Aug 14, 2023

BUY
$11.5 - $18.08 $130,157 - $204,629
11,318 New
11,318 $152,000
Q3 2022

Nov 14, 2022

BUY
$7.06 - $15.52 $185,190 - $407,105
26,231 New
26,231 $337,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.38B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Center Book Partners LP Portfolio

Follow Center Book Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Center Book Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Center Book Partners LP with notifications on news.